<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1254805</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Meta-analysis of the association between toll-like receptor gene polymorphisms and hepatitis C virus infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Du</surname> <given-names>Yuxuan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/2361681/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Shumin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Xinyu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Jialu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gao</surname> <given-names>Yan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lv</surname> <given-names>Weimiao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/2399150/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Ping</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname> <given-names>Haiyan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Luan</surname> <given-names>Junwen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/796333/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname> <given-names>Leiliang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/405413/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>School of Clinical and Basic Medical Sciences &#x00026; Institute of Basic Medical Sciences, Shandong First Medical University &#x00026; Shandong Academy of Medical Sciences</institution>, <addr-line>Jinan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>School of Public Health, Shandong First Medical University &#x00026; Shandong Academy of Medical Sciences</institution>, <addr-line>Jinan</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Elias Adel Rahal, American University of Beirut, Lebanon</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Hoda Hagrass, University of Arkansas for Medical Sciences, United States; Enass Abdel-Hameed, University of Cincinnati, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Junwen Luan <email>adist_2008&#x00040;163.com</email></corresp>
<corresp id="c002">Leiliang Zhang <email>armzhang&#x00040;hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1254805</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2023 Du, Li, Wang, Liu, Gao, Lv, Liu, Huang, Luan and Zhang.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Du, Li, Wang, Liu, Gao, Lv, Liu, Huang, Luan and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The objective of this study is to investigate the association between toll-like receptor (TLR) 3/7 gene polymorphisms and the infection by hepatitis C virus (HCV).</p></sec>
<sec>
<title>Methods</title>
<p>PubMed, Embase, Web of Science, Scopus, CNKI, Wanfang Data, and SinoMed were searched to identify studies focusing on the association between the TLR3 rs3775290 or the TLR7 rs179008 single nucleotide polymorphisms (SNPs) and the HCV infection. All the related articles were collected from the inception of each database to 15 January 2023. Our meta-analysis was conducted using the allelic model, the dominant model, and the recessive model. Outcomes were presented by odds ratio (ORs) and 95% confidence interval (95%CI). The heterogeneity across studies was assessed by the I<sup>2</sup> test. A subgroup analysis was performed to explore the source of heterogeneity. Funnel plots were drawn to assess the risk of publication bias. Review Manager 5.4 was used for statistical analysis.</p></sec>
<sec>
<title>Results</title>
<p>Ten articles were finally included, among which six studies were analyzed for rs3775290 and five studies were analyzed for rs179008. Studies relating to rs3775290 included 801 patients and 1,045 controls, whereas studies relating to rs179008 included 924 patients and 784 controls. The results of the meta-analysis showed that there is no significant association between rs3775290 gene polymorphism and HCV infection (T vs. C: OR = 1.12, 95%CI 0.97&#x02013;1.30; TT&#x0002B;CT vs. CC: OR = 1.20, 95%CI 0.73&#x02013;1.96; TT vs. CT&#x0002B;CC: OR = 1.13, 95%CI 0.68&#x02013;1.89). The recessive model showed that rs179008-T allele homozygotes had an 89% increased risk of infection by HCV compared with rs179008-A allele carriers (TT vs. AT&#x0002B;AA: OR = 1.89, 95%CI 1.13&#x02013;3.16). The results of the subgroup analysis demonstrated that the characteristics of the control population may serve as an important source of heterogeneity. In the African populations, individuals with homozygous rs179008-T alleles had a higher risk of infection by HCV than rs179008-A allele carriers (OR = 2.14, 95%CI 1.18&#x02013;3.87). We did not find that this difference existed in the European populations (OR = 1.24, 95%CI 0.43&#x02013;3.56).</p></sec>
<sec>
<title>Conclusion</title>
<p>There is no significant association between rs3775290 single nucleotide polymorphism and the infection by HCV. Individuals with homozygous rs179008-T alleles have a higher risk of an infection by HCV than rs179008-A allele carriers, which is statistically significant in the African populations.</p></sec></abstract>
<kwd-group>
<kwd>hepatitis C (HCV)</kwd>
<kwd>virus</kwd>
<kwd>toll-like receptor (TLR)</kwd>
<kwd>single nucleotide polymorphisms (SNP)</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="43"/>
<page-count count="13"/>
<word-count count="7053"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Virology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Hepatitis C is a major infectious disease caused by persistent infections of human hepatocytes by hepatitis C virus (HCV), which can lead to liver fibrosis, cirrhosis, and liver cancer. Dramatic breakthroughs have been made in the use of direct-acting antiviral agents (DAAs) for the treatment of hepatitis C. However, more than 58 million people worldwide are still infected with HCV. Among patients with the three types of viral hepatitis (hepatitis A, B, and C), HCV-infected patients accounted for the greatest number of deaths and the highest mortality rate (Basit et al., <xref ref-type="bibr" rid="B6">2023</xref>). HCV is widely spread worldwide, but no vaccine has emerged so far to prevent hepatitis C. Therefore, assessing the difference in the rates of HCV infections among different populations is of vital significance for the precise treatment of patients suffering from HCV-induced hepatitis or liver cancer, both theoretically and practically.</p>
<p>Toll-like receptors (TLRs) belong to the innate immune receptor family and play an important role in activating innate immunity, regulating the expression of cytokines, activating the adaptive immune system indirectly, and recognizing pathogen-associated molecular patterns (Hedayat et al., <xref ref-type="bibr" rid="B15">2011</xref>). There are 10 family members of TLRs that exist in humans. Some of these TLRs are located on the cell membrane, while others are located on intracellular endosomes, such as TLR3, TLR7, TLR8, and TLR9. TLRs are expressed in different immune cells, such as dendritic cells (DCs), macrophages, natural killer (NK) cells, and adaptive immune cells (T and B cells) (Lester and Li, <xref ref-type="bibr" rid="B20">2014</xref>). It has been demonstrated that different TLRs recognize different pathogen-associated molecular patterns, with TLR3 predominantly recognizing dsRNA (Alexopoulou et al., <xref ref-type="bibr" rid="B3">2001</xref>), whereas TLR7 predominantly recognizes ssRNA (Kawai and Akira, <xref ref-type="bibr" rid="B18">2011</xref>). As one of the best-studied pathogen recognition receptor families, the toll-like receptor family plays a key role in infections by HCV (Kayesh et al., <xref ref-type="bibr" rid="B19">2022</xref>).</p>
<p>To date, there are a huge number of clinical studies on the association between single nucleotide polymorphisms (SNPs) of TLR3/7 genes and HCV-induced liver diseases, of which studies on TLR3 rs3775290 SNP and TLR7 rs179008 SNP occupy a large proportion. However, the conclusions obtained are not consistent. Therefore, we comprehensively evaluated related studies on the association between TLR3/7 gene SNPs and infections by HCV through meta-analysis to reveal the differences in the susceptibility to HCV of different individuals, providing clues for precise treatment and prognostic evaluation of HCV-infected individuals.</p>
</sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and methods</title>
<sec>
<title>Search strategy</title>
<p>We searched PubMed, Embase, Web of Science, Scopus, CNKI, Wanfang Data, and SinoMed to collect associated studies on TLR gene polymorphisms and infections by HCV, with the last search term on 15 January 2023. Search terms included &#x0201C;TLR,&#x0201D; &#x0201C;Toll-Like Receptor,&#x0201D; &#x0201C;HCV,&#x0201D; &#x0201C;Hepatitis C,&#x0201D; &#x0201C;Hepacivirus,&#x0201D; &#x0201C;polymorphism,&#x0201D; and &#x0201C;mutation.&#x0201D; Taking PubMed as an example, the specific search formulas are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Search formulas in PubMed.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-14-1254805-g0001.tif"/>
</fig>
</sec>
<sec>
<title>Inclusion and exclusion criteria</title>
<p>Inclusion criteria are as follows: (1) published articles whose full text is accessible; (2) case&#x02013;control study or cohort study involving the relationship between TLR3 rs3775290 or TLR7 rs179008 single nucleotide polymorphisms (SNPs) and infections by HCV; (3) articles that we can extract the frequency of related genes through the original literature, authors, or relevant departments; (4) articles that we can obtain required OR value and 95%CI from the original data or by mathematical conversions.</p>
<p>Exclusion criteria are as follows: (1) articles that are not related to TLR3, TLR7, SNPs, or HCV-infected clinical populations; (2) studies of animal experiments; (3) articles that are unable to access the full text; (4) repeated publications; (5) articles without complete data, for instance, allele or genotype information is missing or unable to calculate.</p>
</sec>
<sec>
<title>Data extraction and quality assessment</title>
<p>Two investigators searched each database with the same search strategy and screened the articles according to the inclusion and exclusion criteria independently. Then, they extracted data and assessed the quality of the included articles. Data items are as follows: (1) first author; (2) publication year; (3) country of the study population; (4) SNP information (allele and genotype frequencies) and sample sizes of the HCV group and control group; (5) type of study design; (6) source of control; (7) genetic testing method. Quality assessment of each study was performed using the Newcastle&#x02013;Ottawa Scale (NOS) (Stang, <xref ref-type="bibr" rid="B38">2010</xref>). The NOS consists of three parts: selection of study subjects, comparability between the groups, and measurement of exposure factors; the full scores of each part are 4, 2, and 3 points, respectively. Based on the highest score of 9 points, studies with scores of 7 points and above are considered as high-quality studies. Disagreements between the two investigators during the process of data extraction and quality assessment were resolved by a discussion with the third party.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Hardy&#x02013;Weinberg equilibrium (HWE) testing was conducted on the control group of each study using the &#x003C7;2 test. Applying the allelic model, the dominant model, and the recessive model, our meta-analysis was performed, and the outcomes were presented by odds ratio (OR) and 95% confidence interval (95% CI). Heterogeneity across each included study was evaluated using the I<sup>2</sup> statistic (Higgins and Thompson, <xref ref-type="bibr" rid="B16">2002</xref>). A fixed-effect model was used when the heterogeneity among studies was not significant (I<sup>2</sup> &#x0003C; 50%), otherwise a random-effect model was used (I<sup>2</sup> &#x0003E; 50%), following a subgroup analysis to explore the source of heterogeneity. Funnel plots were drawn to assess the publication bias. All statistical analyses above were completed by Review Manager 5.4 except for HWE tests.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Search results</title>
<p>Seven databases, namely, PubMed, Embase, Web of Science, Scopus, CNKI, Wanfang Data, and SinoMed were initially retrieved to obtain 303 potentially relevant articles. Ten articles (Sizova et al., <xref ref-type="bibr" rid="B37">2016</xref>; Chi et al., <xref ref-type="bibr" rid="B8">2017</xref>; Fakhir et al., <xref ref-type="bibr" rid="B11">2017</xref>; Valverde-Villegas et al., <xref ref-type="bibr" rid="B41">2017</xref>; Zayed et al., <xref ref-type="bibr" rid="B43">2017</xref>; Hamdy et al., <xref ref-type="bibr" rid="B14">2018</xref>; Malov et al., <xref ref-type="bibr" rid="B22">2018</xref>; Mosaad et al., <xref ref-type="bibr" rid="B27">2018</xref>; Sghaier et al., <xref ref-type="bibr" rid="B35">2018</xref>; Abdelwahab et al., <xref ref-type="bibr" rid="B1">2020</xref>) were involved in the meta-analysis, including six studies about rs3775290 and five studies about rs179008, after removing 111 duplicate articles, 143 articles unrelated to the selected Reference SNP ID (rs), and 39 articles that could not extract information for the meta-analysis. The literature retrieval and screening process are presented in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Flow diagram of retrieval and screening processes.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-14-1254805-g0002.tif"/>
</fig>
</sec>
<sec>
<title>Study characteristics and quality assessment results</title>
<p>The basic characteristics of studies involved in the meta-analysis are shown in <xref ref-type="table" rid="T1">Table 1</xref>, including allele and genotype distributions. The selected studies contain populations from seven countries, covering many regions, such as Africa, Europe, and Asia. All of them are case&#x02013;control studies. Two populations do not meet the standards of HWE balance (Valverde-Villegas et al., <xref ref-type="bibr" rid="B41">2017</xref>; Malov et al., <xref ref-type="bibr" rid="B22">2018</xref>). The quality assessment results of involved studies using the Newcastle&#x02013;Ottawa Scale are presented in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Characteristics of studies involved in the meta-analysis.</p></caption>
<table frame="box" rules="all">
<thead>
<tr style="background-color:&#x00023;919498;color:&#x00023;ffffff">
<th valign="top" align="left"><bold>Study</bold></th>
<th valign="top" align="left"><bold>Country</bold></th>
<th valign="top" align="left"><bold>Controls</bold></th>
<th valign="top" align="center"><bold>Sample size<xref ref-type="table-fn" rid="TN1"><sup>&#x0002A;</sup></xref></bold></th>
<th valign="top" align="center" colspan="5"><bold>Distribution of genotype and allele</bold></th>
<th valign="top" align="left"><bold>Genotyping method</bold></th>
<th valign="top" align="center"><bold>P<sub>HWE</sub></bold></th>
</tr>
</thead>
<tbody>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="4"><bold>rs3775290(TLR3)</bold></td>
<td valign="top" align="center"><bold>CC</bold></td>
<td valign="top" align="center"><bold>CT</bold></td>
<td valign="top" align="center"><bold>TT</bold></td>
<td valign="top" align="center"><bold>C</bold></td>
<td valign="top" align="center"><bold>T</bold></td>
<td/>
<td/>
</tr> <tr>
<td valign="top" align="left">Mosaad et al. (<xref ref-type="bibr" rid="B27">2018</xref>)</td>
<td valign="top" align="left">Egypt</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">100/100</td>
<td valign="top" align="center">6/37</td>
<td valign="top" align="center">90/50</td>
<td valign="top" align="center">4/13</td>
<td valign="top" align="center">102/124</td>
<td valign="top" align="center">98/76</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.541</td>
</tr> <tr>
<td valign="top" align="left">Abdelwahab et al. (<xref ref-type="bibr" rid="B1">2020</xref>)</td>
<td valign="top" align="left">Egypt</td>
<td valign="top" align="left">Seronegative health-care workers</td>
<td valign="top" align="center">70/159</td>
<td valign="top" align="center">46/105</td>
<td valign="top" align="center">18/46</td>
<td valign="top" align="center">6/8</td>
<td valign="top" align="center">110/256</td>
<td valign="top" align="center">30/62</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.323</td>
</tr> <tr>
<td valign="top" align="left">Sghaier et al. (<xref ref-type="bibr" rid="B35">2018</xref>)</td>
<td valign="top" align="left">Tunisia</td>
<td valign="top" align="left">Seronegative individuals</td>
<td valign="top" align="center">174/360</td>
<td valign="top" align="center">77/157</td>
<td valign="top" align="center">51/149</td>
<td valign="top" align="center">46/54</td>
<td valign="top" align="center">205/463</td>
<td valign="top" align="center">143/257</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.062</td>
</tr> <tr>
<td valign="top" align="left">Hamdy et al. (<xref ref-type="bibr" rid="B14">2018</xref>)</td>
<td valign="top" align="left">Egypt</td>
<td valign="top" align="left">Seronegative health-care workers</td>
<td valign="top" align="center">235/284</td>
<td valign="top" align="center">141/170</td>
<td valign="top" align="center">78/95</td>
<td valign="top" align="center">16/19</td>
<td valign="top" align="center">360/435</td>
<td valign="top" align="center">110/133</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.257</td>
</tr> <tr>
<td valign="top" align="left">Zayed et al. (<xref ref-type="bibr" rid="B43">2017</xref>)</td>
<td valign="top" align="left">Egypt</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">100/100</td>
<td valign="top" align="center">66/55</td>
<td valign="top" align="center">28/39</td>
<td valign="top" align="center">6/6</td>
<td valign="top" align="center">160/149</td>
<td valign="top" align="center">40/51</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.791</td>
</tr> <tr>
<td valign="top" align="left">Chi et al. (<xref ref-type="bibr" rid="B8">2017</xref>)</td>
<td valign="top" align="left">China</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">122/42</td>
<td valign="top" align="center">37/12</td>
<td valign="top" align="center">41/16</td>
<td valign="top" align="center">44/14</td>
<td valign="top" align="center">115/40</td>
<td valign="top" align="center">129/44</td>
<td valign="top" align="left">SNPscanTM Multiplex SNP Typing Kit</td>
<td valign="top" align="center">0.126</td>
</tr> 
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="4"><bold>rs179008(TLR7)</bold></td>
<td valign="top" align="center"><bold>AA</bold></td>
<td valign="top" align="center"><bold>AT</bold></td>
<td valign="top" align="center"><bold>TT</bold></td>
<td valign="top" align="center"><bold>A</bold></td>
<td valign="top" align="center"><bold>T</bold></td>
<td valign="top" align="center" colspan="2"></td>
</tr> 
<tr>
<td valign="top" align="left">Mosaad et al. (<xref ref-type="bibr" rid="B27">2018</xref>)</td>
<td valign="top" align="left">Egypt</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">30/30</td>
<td valign="top" align="center">13/11</td>
<td valign="top" align="center">10/14</td>
<td valign="top" align="center">7/5</td>
<td valign="top" align="center">144/138</td>
<td valign="top" align="center">56/62</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.880</td>
</tr> <tr>
<td valign="top" align="left">Fakhir et al. (<xref ref-type="bibr" rid="B11">2017</xref>)</td>
<td valign="top" align="left">Morocco</td>
<td valign="top" align="left">Individuals without liver diseases</td>
<td valign="top" align="center">246/72</td>
<td valign="top" align="center">85/33</td>
<td valign="top" align="center">83/27</td>
<td valign="top" align="center">78/12</td>
<td valign="top" align="center">312/133</td>
<td valign="top" align="center">346/77</td>
<td valign="top" align="left">TaqMan allelic discrimination assays, PCR-RFLP</td>
<td valign="top" align="center">0.123</td>
</tr> <tr>
<td valign="top" align="left" rowspan="2">Valverde-Villegas et al. (<xref ref-type="bibr" rid="B41">2017</xref>)</td>
<td valign="top" align="left">Brazil (European descendants)</td>
<td valign="top" align="left">HIV-infected individuals</td>
<td valign="top" align="center">16/81</td>
<td valign="top" align="center" colspan="2">10/57</td>
<td valign="top" align="center">6/24</td>
<td valign="top" align="center">22/64</td>
<td valign="top" align="center">2/13</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.802</td>
</tr>
 <tr>
<td valign="top" align="left">Brazil (African descendants)</td>
<td valign="top" align="left">HIV-infected individuals</td>
<td valign="top" align="center">19/45</td>
<td valign="top" align="center" colspan="2">12/33</td>
<td valign="top" align="center">7/12</td>
<td valign="top" align="center">32/43</td>
<td valign="top" align="center">6/13</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.050</td>
</tr> <tr>
<td valign="top" align="left">Malov et al. (<xref ref-type="bibr" rid="B22">2018</xref>)</td>
<td valign="top" align="left">Russia</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">120/132</td>
<td valign="top" align="center">99/119</td>
<td valign="top" align="center">15/10</td>
<td valign="top" align="center">6/3</td>
<td valign="top" align="center">213/248</td>
<td valign="top" align="center">27/16</td>
<td valign="top" align="left">AmpliSense-HCV-genotype kit, real-time PCR</td>
<td valign="top" align="center">0.000</td>
</tr> <tr>
<td valign="top" align="left">Sizova et al. (<xref ref-type="bibr" rid="B37">2016</xref>)</td>
<td valign="top" align="left">Ukraine</td>
<td valign="top" align="left">Healthy individuals</td>
<td valign="top" align="center">125/85</td>
<td valign="top" align="center">102/63</td>
<td valign="top" align="center">21/19</td>
<td valign="top" align="center">2/3</td>
<td valign="top" align="center">225/145</td>
<td valign="top" align="center">25/25</td>
<td valign="top" align="left">PCR-RFLP</td>
<td valign="top" align="center">0.460</td>
</tr></tbody>
</table>
<table-wrap-foot>
<fn id="TN1"><label>&#x0002A;</label><p>HCV group/control group; PCR-RFLP, PCR-restriction fragment length polymorphism; some P<sub><italic>HWE</italic></sub> values were obtained directly from the original text of the study, the investigator calculated it and retained three decimal places when there was no information of P<sub><italic>HWE</italic></sub> value in the original text, P<sub><italic>HWE</italic></sub> &#x0003C; 0.05 indicates that it does not conform to Hardy-Weinberg equilibrium; The TLR7 rs179008 gene polymorphism occurs on the X chromosome, so only the female population is used as study objects in principle when counting the genotype distribution; In Valverde-Villegas et al. (<xref ref-type="bibr" rid="B9">2017</xref>) studies, the sample size of genotype AT and TT only showed the sum of these two because the data provided in the original article was not detailed.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Quality assessment of involved studies.</p></caption> 
<table frame="box" rules="all">
<thead>
<tr style="background-color:&#x00023;919498;color:&#x00023;ffffff">
<th valign="top" align="left"><bold>References</bold></th>
<th valign="top" align="center"><bold>Selection of study subjects</bold></th>
<th valign="top" align="center"><bold>Comparability between groups</bold></th>
<th valign="top" align="center"><bold>Measurement of exposure factors</bold></th>
<th valign="top" align="center"><bold>NOS score</bold></th>
</tr>
</thead>
<tbody>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="5"><bold>rs3775290(TLR3)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Mosaad et al. (<xref ref-type="bibr" rid="B27">2018</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">Abdelwahab et al. (<xref ref-type="bibr" rid="B1">2020</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">Sghaier et al. (<xref ref-type="bibr" rid="B35">2018</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">Hamdy et al. (<xref ref-type="bibr" rid="B14">2018</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">Zayed et al. (<xref ref-type="bibr" rid="B43">2017</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Chi et al. (<xref ref-type="bibr" rid="B8">2017</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">8</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="5"><bold>rs179008(TLR7)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Mosaad et al. (<xref ref-type="bibr" rid="B27">2018</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">9</td>
</tr>
<tr>
<td valign="top" align="left">Fakhir et al. (<xref ref-type="bibr" rid="B11">2017</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">9</td>
</tr>
<tr>
<td valign="top" align="left">Valverde-Villegas et al. (<xref ref-type="bibr" rid="B41">2017</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1.5</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">8.5</td>
</tr>
<tr>
<td valign="top" align="left">Malov et al. (<xref ref-type="bibr" rid="B22">2018</xref>)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Sizova et al. (<xref ref-type="bibr" rid="B37">2016</xref>)</td>
<td valign="top" align="center">3.5</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">7.5</td>
</tr></tbody>
</table>
<table-wrap-foot>
<p>Literature quality assessment was completed independently by two investigators, and the scores shown in the table are the mean values.</p>
</table-wrap-foot>
</table-wrap>
<p>Rs3775290 of TLR3 is located on the human autosome. Six studies on rs3775290 contain 1,846 subjects, including 801 patients and 1,045 controls. Rs179008 of TLR7 is located on the human X chromosome. In principle, the allelic model is based on all the subjects involved, while the dominant model and the recessive model are based only on female subjects. The study by Valverde-Villegas et al. (<xref ref-type="bibr" rid="B41">2017</xref>) is an exception for the allelic model, only focused on males of the subjects according to the original data. Five studies on rs179008 contain 1,001 female subjects including 556 patients and 445 controls and 707 male subjects including 368 patients and 339 controls.</p>
</sec>
<sec>
<title>Meta-analysis results</title>
<p>Meta-analysis results of the association between TLR3/7 gene polymorphisms and infections by HCV are summarized in <xref ref-type="table" rid="T3">Table 3</xref>. Forest plots of each genetic model are shown in <xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4</xref>.</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Meta-analysis results of the association between TLR gene polymorphisms and HCV infection.</p></caption> 
<table frame="box" rules="all">
<thead>
<tr style="background-color:&#x00023;919498;color:&#x00023;ffffff">
<th valign="top" align="left"><bold>Genetic model</bold></th>
<th valign="top" align="center"><bold>Number of studies</bold></th>
<th valign="top" align="center"><bold>HCV group/</bold><break/> <bold>control group</bold></th>
<th valign="top" align="center"><bold>I<sup>2</sup></bold></th>
<th valign="top" align="center"><bold>Statistical effect model</bold></th>
<th valign="top" align="center"><bold>OR,95%CI</bold></th>
</tr>
</thead>
<tbody>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="6"><bold>rs3775290</bold></td>
</tr>
<tr>
<td valign="top" align="left">Allelic model (T vs. C)</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">1602/2090</td>
<td valign="top" align="center">32%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.12[0.97,1.30]</td>
</tr>
<tr>
<td valign="top" align="left">Dominant model (TT&#x0002B;CT vs. CC)</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">801/1045</td>
<td valign="top" align="center">80%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.20[0.73,1.96]</td>
</tr>
<tr>
<td valign="top" align="left">Recessive model (TT vs. CT&#x0002B;CC)</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">801/1045</td>
<td valign="top" align="center">58%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.13[0.68,1.89]</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="6"><bold>rs179008</bold></td>
</tr>
<tr>
<td valign="top" align="left">Allelic model (T vs. A)</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">1410/977</td>
<td valign="top" align="center">75%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.05[0.64,1.71]</td>
</tr>
<tr>
<td valign="top" align="left">Dominant model (TT&#x0002B;AT vs. AA)</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">556/445</td>
<td valign="top" align="center">30%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.25[0.91,1.71]</td>
</tr>
<tr>
<td valign="top" align="left">Recessive model (TT vs. AT&#x0002B;AA)</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">521/319</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.89[1.13,3.16]</td>
</tr></tbody>
</table>
<table-wrap-foot>
<p>I<sup>2</sup>, the Inconsistency statistics; OR, odds ratio; CI, confidence interval; F, fixed-effect model; R, random-effect model.</p>
</table-wrap-foot>
</table-wrap>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Forest plots of the association between rs3775290 and HCV infection. <bold>(A)</bold> Allelic model (T vs. C). <bold>(B)</bold> Dominant model (TT&#x0002B;CT vs. CC). <bold>(C)</bold> Recessive model (TT vs. CT&#x0002B;CC).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-14-1254805-g0003.tif"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>Forest plots of the association between rs179008 and HCV infection. <bold>(A)</bold> Allelic model (T vs. A). <bold>(B)</bold> Dominant model (TT&#x0002B;AT vs. AA). <bold>(C)</bold> Recessive model (TT vs. AT&#x0002B;AA).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-14-1254805-g0004.tif"/>
</fig>
<sec>
<title>Forest plots of genetic models and their interpretations</title>
<p>Allele frequencies of rs3775290-T are 34.33% and 29.81% in the HCV group and control group, respectively. In the allelic model (<xref ref-type="fig" rid="F3">Figure 3A</xref>), the fixed-effect model showed a pooled OR and 95%CI of 1.12[0.97, 1.30], with the allele T as the exposure factor and the allele C as the non-exposure factor. In the dominant model (<xref ref-type="fig" rid="F3">Figure 3B</xref>), the random-effect model showed a pooled OR and 95%CI of 1.20[0.73, 1.96], with the genotype TT&#x0002B;CT as the exposure factor and the genotype CC as the non-exposure factor. In the recessive model (<xref ref-type="fig" rid="F3">Figure 3C</xref>), the random-effect model showed a pooled OR and 95%CI of 1.13[0.68, 1.89], with the genotype TT as the exposure factor and the genotypes CT&#x0002B;CC as the non-exposure factor. As a consequence, the association between this <italic>TLR3</italic> gene polymorphism and the infection by HCV cannot yet be considered statistically significant. The details of the results above are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p>
<p>Allele frequencies of rs179008-T are 32.77% and 21.08% in the HCV group and control group, respectively. In the allelic model (<xref ref-type="fig" rid="F4">Figure 4A</xref>), the random-effect model showed a pooled OR and 95%CI of 1.05[0.64, 1.71], with the allele T as the exposure factor and the allele A as the non-exposure factor. In the dominant model (<xref ref-type="fig" rid="F4">Figure 4B</xref>), the fixed-effect model showed a pooled OR and 95%CI of 1.25[0.91, 1.71], with the genotypes TT&#x0002B;AT as the exposure factor and the genotype AA as the non-exposure factor. In the recessive model (<xref ref-type="fig" rid="F4">Figure 4C</xref>), the fixed-effect model showed a pooled OR and 95%CI of 1.89[1.13, 3.16], with the genotype TT as the exposure factor and the genotypes AT&#x0002B;AA as the non-exposure factor, which indicated that the risk of an infection by HCV is increased by 89% in TT homozygotes compared with A allele carriers. The association between this <italic>TLR7</italic> gene polymorphism and the infection by HCV is statistically significant. The details of the results above are shown in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p>
</sec>
<sec>
<title>Subgroup analysis and sensitivity analysis</title>
<p>The results of the heterogeneity tests showed significant heterogeneity in the dominant model (TT &#x0002B; CT vs. CC, I<sup>2</sup> = 80%) and the recessive model (TT vs. CT &#x0002B; CC, I<sup>2</sup> = 58%) of the TLR3 rs3775290 gene polymorphism and in the allelic model (T vs. A, I<sup>2</sup> = 75%) of the <italic>TLR7 rs179008</italic> gene polymorphism. A subgroup analysis was conducted to calculate pooled ORs and their 95%CIs to explore the reasons for heterogeneity due to the high heterogeneity.</p>
<p>The results of the subgroup analysis (<xref ref-type="table" rid="T4">Table 4</xref>) are as follows: (1) The characteristics of the control group may be a common source of heterogeneity in the study on the association between <italic>rs3775290</italic> or <italic>rs179008</italic> gene polymorphism and infections by HCV. In the process of our research, it was found that seronegative individuals generally mean that the study subjects were selected from hospitals. They are either patients from other departments of a hospital or healthcare workers who have come in contact with patients. Therefore, they are different from the ordinary healthy population. In the recessive model associated with rs3775290, when the control group is composed of non-healthy individuals, TT homozygotes have a 66% increased risk of infection by HCV compared with C allele carriers, which is statistically significant (OR = 1.66, 95%CI 1.17&#x02013;2.36). However, when the control group is composed of healthy individuals, there is no statistically significant difference in the risk of infection by HCV between TT homozygotes and C allele carriers (OR = 0.73, 95%CI 0.31&#x02013;1.69). In the dominant model associated with rs179008, when the control group is composed of non-healthy individuals, T allele carriers have a 57% increased risk of infection by HCV compared with AA homozygotes, which is statistically significant (OR = 1.57, 95%CI 1.01&#x02013;2.45). However, when the control group is composed of healthy individuals, there is no statistically significant difference in the risk of infection by HCV between T allele carriers and AA homozygotes (OR = 1.00, 95%CI 0.65&#x02013;1.55). (2) The recessive model on rs179008 showed that there is a statistically significant difference between this <italic>TLR7</italic> gene polymorphism and the infection by HCV. The heterogeneity of this conclusion may come from the regional distribution of the study subjects. Compared with the European population (OR = 1.24, 95%CI 0.43&#x02013;3.56), a higher pooled OR was obtained in the North African population (OR = 2.14, 95%CI 1.18&#x02013;3.87). It suggested that rs179008-T allele homozygotes have a higher risk of infection by HCV than A allele carriers in the North African population, but this difference cannot be considered to exist in the European population.</p>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p>Subgroup analysis and sensitivity analysis of the association between TLR gene polymorphism and HCV infection.</p></caption> 
<table frame="box" rules="all">
<thead>
<tr style="background-color:&#x00023;919498;color:&#x00023;ffffff">
<th valign="top" align="left"><bold>Subgroup</bold></th>
<th valign="top" align="center"><bold>Genetic model</bold></th>
<th valign="top" align="center"><bold>Number of studies</bold></th>
<th valign="top" align="center"><bold>HCV group/ control group</bold></th>
<th valign="top" align="center"><bold>I<sup>2</sup></bold></th>
<th valign="top" align="center"><bold>Statistical effect model</bold></th>
<th valign="top" align="center"><bold>OR,95%CI</bold></th>
</tr>
</thead>
<tbody>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="7"><bold>rs3775290(TLR3)</bold></td>
</tr>
<tr>
<td valign="top" align="left" colspan="7">Control group</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Healthy individuals</td>
<td valign="top" align="center">T vs. C</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">644/484</td>
<td valign="top" align="center">67%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.07[0.68,1.68]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;CT vs. CC</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">322/242</td>
<td valign="top" align="center">92%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.69[0.37,7.66]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. CT&#x0002B;CC</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">322/242</td>
<td valign="top" align="center">52%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">0.73[0.31,1.69]</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Non-healthy individuals</td>
<td valign="top" align="center">T vs. C</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">958/1606</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.13[0.94,1.36]</td>
</tr>
<tr>
<td/>
<td valign="top" align="center">TT&#x0002B;CT vs. CC</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">479/803</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">0.99[0.78,1.25]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. CT&#x0002B;CC</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">479/803</td>
<td valign="top" align="center">27%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.66[1.17,2.36]</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="7">Area</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;North Africa</td>
<td valign="top" align="center">T vs. C</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">1358/2006</td>
<td valign="top" align="center">45%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.13[0.97,1.32]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;CT vs. CC</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">679/1003</td>
<td valign="top" align="center">84%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.27[0.72,2.23]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. CT&#x0002B;CC</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">679/1003</td>
<td valign="top" align="center">65%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.10[0.58,2.09]</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Asia</td>
<td valign="top" align="center">T vs. C</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">244/84</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">1.02[0.62,1.68]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;CT vs. CC</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">122/42</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">0.92[0.42,1.99]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. CT&#x0002B;CC</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">122/42</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">1.13[0.54,2.37]</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="7"><bold>rs179008(TLR7)</bold></td>
</tr>
<tr>
<td valign="top" align="left" colspan="7">Control group</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Healthy individuals</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">690/634</td>
<td valign="top" align="center">70%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.01[0.56,1.81]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">275/247</td>
<td valign="top" align="center">60%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.00[0.65,1.55]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">275/247</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.35[0.60,3.04]</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Non-healthy individuals</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">720/343</td>
<td valign="top" align="center">70%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">0.98[0.36,2.64]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">281/198</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.57[1.01,2.45]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">246/72</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">2.32[1.18,4.56]</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="7">Area</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;North Africa</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">896/466</td>
<td valign="top" align="center">81%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.11[0.56,2.21]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">295/147</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.40[0.90,2.16]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">276/102</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">2.14[1.18,3.87]</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Europe</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">514/511</td>
<td valign="top" align="center">73%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">0.93[0.39,2.31]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">261/298</td>
<td valign="top" align="center">60%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.17[0.56,2.46]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">245/217</td>
<td valign="top" align="center">48%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.24[0.43,3.56]</td>
</tr>
<tr style="background-color:#dee1e1">
<td valign="top" align="left" colspan="7">HWE (sensitivity analysis)</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;Yes</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1132/657</td>
<td valign="top" align="center">81%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">0.96[0.51,1.81]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">417/268</td>
<td valign="top" align="center">41%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.09[0.76,1.57]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">401/187</td>
<td valign="top" align="center">31%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.84[1.06,3.20]</td>
</tr>
<tr>
<td valign="top" align="left">&#x000A0;No</td>
<td valign="top" align="center">T vs. A</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">278/320</td>
<td valign="top" align="center">69%</td>
<td valign="top" align="center">R</td>
<td valign="top" align="center">1.20[0.39,3.67]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT&#x0002B;AT vs. AA</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">139/177</td>
<td valign="top" align="center">0%</td>
<td valign="top" align="center">F</td>
<td valign="top" align="center">1.84[0.99,3.42]</td>
</tr>
 <tr>
<td/>
<td valign="top" align="center">TT vs. AT&#x0002B;AA</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">120/132</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center">2.26[0.55,9.26]</td>
</tr></tbody>
</table>
<table-wrap-foot>
<p>I<sup>2</sup>, the Inconsistency statistics; OR, odds ratio; CI, confidence interval; F, fixed-effect model; R, random-effect model.</p>
</table-wrap-foot>
</table-wrap>
<p>The results of a sensitivity analysis (<xref ref-type="table" rid="T4">Table 4</xref>) showed that the pooled OR (OR = 1.84, 95%CI 1.06&#x02013;3.20) on rs179008 in the recessive model has no essential change after excluding a study whose control group does not meet the standards of Hardy&#x02013;Weinberg equilibrium. It indicated that the sensitivity of our meta-analysis results is low, and the conclusion is steady. For this reason, we can agree that the association between this <italic>TLR7</italic> gene polymorphism and the infection by HCV is statistically significant. Indeed, the risk of an infection by HCV is higher in TT homozygotes than in A allele carriers.</p>
</sec>
</sec>
<sec>
<title>Publication bias assessment</title>
<p>Publication bias was assessed by drawing funnel plots using Review Manager 5.4 software, and the results are shown in <xref ref-type="fig" rid="F5">Figure 5</xref>. In studies on the TLR3 rs3775290, no significant publication bias was observed between the allelic model (T vs. C) and the recessive model (TT vs. CT&#x0002B;CC), but there are some publication biases in the dominant model (TT&#x0002B;CT vs. CC). In studies on the TLR7 rs179008, no significant publication bias was observed between the dominant model (TT&#x0002B;AT vs. AA) and the recessive model (TT vs. AT&#x0002B;AA), but there are some publication biases in the allelic model (T vs. A).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>Funnel plots of publication bias. <bold>(A)</bold> relating to rs3775290(TLR3), <bold>(B)</bold> relating to rs179008(TLR7).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-14-1254805-g0005.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this study, a meta-analysis was performed on the 10 included articles to investigate the association between toll-like receptor single nucleotide polymorphisms and infection by HCV. As the results are revealed, there is no significant association between rs3775290 of TLR3 and the infection by HCV, while the homozygous rs179008-T alleles may increase the risk of HCV infection. However, it does not mean that the rs3775290 SNP is completely unrelated to the infection by HCV. Talaat et al. (<xref ref-type="bibr" rid="B39">2022</xref>) suggested that rs3775290 might be associated with the development of cirrhosis in HCV-infected individuals. The research by Sghaier et al. (<xref ref-type="bibr" rid="B34">2017</xref>) showed a higher frequency of TLR3 rs3775290 C/C genotype in patients with sustained viral response compared with non-responders; TLR3 is involved in the pathogenesis of the infection by HCV and may be more suitable for activating antiviral programs than TLR4.</p>
<p>The recessive model showed that rs179008-T allele homozygotes have an 89% increased risk of an infection by HCV compared with A allele carriers. The results of the subgroup analysis demonstrated that the association between TLR7 rs179008 SNP and the infection by HCV is statistically significant in the North African population but not in the European population. However, one thing we should pay more attention to is that it is crucial for researchers to consider and address the potential genetic diversity within the study population to ensure accurate and reliable results. For instance, if a study is conducted in an African country, it is reasonable to assume that the subjects involved are predominantly of African descent. African countries typically have populations composed primarily of individuals with African ancestry. However, it is important to note that individual genetic backgrounds can vary within populations, and there may be some degree of genetic diversity even within a specific geographical region.</p>
<p>Due to certain commonalities of viruses, research studies on relevant viruses have guiding significance for further exploration of the mechanism of how the rs179008 SNP affects the susceptibility to HCV. Oh et al. (<xref ref-type="bibr" rid="B28">2009</xref>) reported that the polymorphism of Gln11Leu on TLR7, which is encoded by the rs179008-T allele, is associated with a high viral load and the progression of immunosuppression in patients with human immunodeficiency virus (HIV). Said et al. (<xref ref-type="bibr" rid="B32">2014</xref>) found that Gln11Leu on TLR7 may be associated with a rapid decrease in CD4T cell count during viremia caused by HIV. These two conclusions are consistent with the results of a systematic review written by Shi et al. (<xref ref-type="bibr" rid="B36">2020</xref>), which showed that the rs179008-T allele has a risk effect on the infection by HIV. A study by Sengupta et al. (<xref ref-type="bibr" rid="B33">2021</xref>) showed that the rs179008 SNP affects the prevalence and the viral load of chikungunya virus (CHIKV) and dengue virus (DENV). Compared with the wild TLR7-rs179008Q, the TLR7-rs179008L variant located in the signal peptide region is more hydrophobic and smaller, which might disturb the recognition of signal peptides. Moreover, the docking of TLR7 with SPC18 shows that the combination of the TLR7-rs179008Q variant and SPC18 is superior to the L variant, considering the change in free energy and more residues of the Q variant docking with SPC18. In future, we can focus more on the relationship between TLR7 gene polymorphism and the viral load, the immunosuppression progression and the T-cell count in patients with hepatitis C. Furthermore, an increasing number of evidence has demonstrated that B-cell lymphoproliferative disorders such as mixed cryoglobulinemia (MC) are related to HCV infection. In the research by Liao et al. (<xref ref-type="bibr" rid="B21">2021</xref>), they confirmed that HCV-induced GU-enriched miRNA (e.g., miR-122, let-7b, and miR-206) could upregulate the expression of B-cell activating factor (BAFF) through exosome transmission and TLR7 activation.</p>
<p>When the control group was composed of healthy individuals, no significant association could be considered to exist between the TLR3 rs3775290 SNP or TLR7 rs179008 SNP and the infection by HCV, based on the pooled ORs and their 95%CIs of each genetic model. However, when the selection criteria for the control group were only seronegative individuals or patients without liver disease, the pooled ORs of some genetic models showed that the rs3775290 and rs179008 are associated with the infection by HCV. The results of the subgroup analysis, according to whether the control group is composed of healthy individuals or not, suggested that there may be other potential confounding factors affecting the meta-analysis results. Mazzaro et al. (<xref ref-type="bibr" rid="B23">2021</xref>) found that lots of experimental and clinical data showed a causal association between extrahepatic diseases and infection by HCV, such as mixed cryoglobulinemia, non-Hodgkin lymphoma (NHL), neurological and psychiatric disorders, insulin resistance, type 2 diabetes, cardiovascular diseases, and certain rheumatic diseases. Extrahepatic diseases may influence the immune status of the body and that might be the reason why they affect the association analysis between toll-like receptor single nucleotide gene polymorphisms and the infection by HCV. In addition to hepatitis C, the rs179008 SNP is also associated with diseases such as sarcoidosis (Bordignon et al., <xref ref-type="bibr" rid="B7">2013</xref>), basal cell carcinoma (BCC) (Piaserico et al., <xref ref-type="bibr" rid="B29">2015</xref>; Russo et al., <xref ref-type="bibr" rid="B30">2016</xref>), melanoma (Sabado et al., <xref ref-type="bibr" rid="B31">2015</xref>), and asthma (M&#x000F8;ller-Larsen et al., <xref ref-type="bibr" rid="B26">2008</xref>; T&#x000F6;rm&#x000E4;nen et al., <xref ref-type="bibr" rid="B40">2017</xref>). These diseases may have undiscovered impacts on the infection by HCV, which indirectly reflects in the association between the <italic>TLR7</italic> gene polymorphism and the susceptibility to HCV, interfering with our judgment of the statistical analysis results.</p>
<p>Pattern recognition receptors (PRRs), which can directly recognize certain specific and shared molecular structures of foreign pathogens and their products, exist on the surface of innate immune cells, on the membrane of intracellular organelles, and in the cytoplasm and blood. Toll-like receptors are members of the pattern recognition receptor family. In addition to toll-like receptors, other PRRs such as mannose receptors (Andersen et al., <xref ref-type="bibr" rid="B4">2014</xref>; Gantzel et al., <xref ref-type="bibr" rid="B12">2020</xref>), scavenger receptors (Grove et al., <xref ref-type="bibr" rid="B13">2007</xref>; Dao Thi et al., <xref ref-type="bibr" rid="B10">2011</xref>), and NOD-like receptors (Aggan et al., <xref ref-type="bibr" rid="B2">2022</xref>) are also associated with HCV infection. Pathogen-associated molecular patterns (PAMPs) are ligand molecules that pattern recognition receptors recognize and bind to. Different PRRs correspond to different PAMPs, but some of their similarities suggest that these receptors may have similar effects on HCV infection, which expands new ideas for exploring the mechanism of TLRs affecting HCV infection.</p>
<p>Askar et al. (<xref ref-type="bibr" rid="B5">2010</xref>) found that the rs179008 gene polymorphism is associated with the differences in the gene expression of interleukin-29 (IL-29)/&#x003BB;1 interferon (IFN-&#x003BB;1) and IFN-&#x003BB; receptor in the livers of HCV-infected individuals. These differences may be important for the effect of the IFN-&#x003BB;-based treatment of hepatitis C. In terms of vaccines, the Rotarix vaccine is currently the most commonly used live oral rotavirus vaccine. Miya et al. (<xref ref-type="bibr" rid="B25">2021</xref>) believed that the TLR7 variant caused by the rs179008 SNP may affect the production of IgA antibodies and the serum conversion after receiving the Rotarix vaccine in black South African infants. It is worth noting that the above-mentioned research results can provide ideas for the transformation from our study to clinical applications.</p>
<p>This study has some limitations. First, the number of included studies is small. When performing the subgroup analysis related to rs3775290 of TLR3, the Asian region only referred to one article; thus, we cannot draw a reliable comprehensive conclusion. It is urgent to carry out more large-sample and high-quality studies in Asian regions, in order to continue investigating the link between the TLR3 rs3775290 gene polymorphism and infections by HCV. Second, the publication bias was evaluated based on the symmetry of funnel plots, but the visual inspection decided that the evaluation results were subjective. Apart from the publication bias, the selection bias, the language bias, and the citation bias, other factors may also affect the symmetry of the funnel plots.</p>
<p>In conclusion, HCV, as a single-stranded RNA virus, can be divided into six genotypes according to its different genomic nucleotide sequences. The genotype of HCV is a vital factor in predicting a sustained viral response. Except for the genotype of HCV, gene polymorphisms of the host can also affect the infection, the therapeutic effect, the prognosis of hepatitis C (Xu et al., <xref ref-type="bibr" rid="B42">2013</xref>), and even the severity of a recurrence of hepatitis C after liver transplantation (Citores et al., <xref ref-type="bibr" rid="B9">2016</xref>). Studies have shown that the host interleukin-28 (IL-28) (Mi et al., <xref ref-type="bibr" rid="B24">2012</xref>) and the gene polymorphisms of human leukocyte antigen (HLA) (Huang et al., <xref ref-type="bibr" rid="B17">2014</xref>) are associated with infections by HCV. In our study, we focused on the single nucleotide gene polymorphism of toll-like receptors, a host genetic factor. We conducted a comprehensive quantitative analysis based on the results of a number of studies to provide support for the in-depth study of the rs3775290 or the rs179008. The results enable us to have new ideas about individualized precise prevention and treatment for groups at risk of HCV.</p>
</sec>
<sec sec-type="author-contributions" id="s5">
<title>Author contributions</title>
<p>YD: Formal analysis, Writing&#x02014;original draft, Writing&#x02014;review and editing. SL: Data curation, Writing&#x02014;original draft. XW: Data curation, Writing&#x02014;original draft. JLi: Resources, Writing&#x02014;original draft. YG: Resources, Writing&#x02014;original draft. WL: Writing&#x02014;original draft. PL: Writing&#x02014;original draft. HH: Writing&#x02014;review and editing. JLu: Conceptualization, Supervision, Writing&#x02014;review and editing. LZ: Funding acquisition, Supervision, Writing&#x02014;review and editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="s6">
<title>Funding</title>
<p>This research was funded by the Natural Science Foundation General Project of Shandong Province (ZR2020MH299), the Student Research Training Program of Shandong First Medical University (2022104391196 and 202310439014), Academic Promotion Programme of Shandong First Medical University (2019LJ001), and the Undergraduate Science and Technology Innovation Plan of International Class of Clinical Medicine in Shandong First Medical University (KC2021-014).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s7">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdelwahab</surname> <given-names>S. F.</given-names></name> <name><surname>Hamdy</surname> <given-names>S.</given-names></name> <name><surname>Osman</surname> <given-names>A. M.</given-names></name> <name><surname>Zakaria</surname> <given-names>Z. A.</given-names></name> <name><surname>Galal</surname> <given-names>I.</given-names></name> <name><surname>Sobhy</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers</article-title>. <source>Clin. Exp. Immunol.</source> <volume>203</volume>, <fpage>3</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/cei.13514</pub-id><pub-id pub-id-type="pmid">32939755</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggan</surname> <given-names>H. E.</given-names></name> <name><surname>Mahmoud</surname> <given-names>S.</given-names></name> <name><surname>Deeb</surname> <given-names>N. E.</given-names></name> <name><surname>Eleishi</surname> <given-names>I.</given-names></name> <name><surname>El-Shendidi</surname> <given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease</article-title>. <source>Sci. Rep.</source> <volume>12</volume>, <fpage>19528</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-22022-5</pub-id><pub-id pub-id-type="pmid">36376416</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulou</surname> <given-names>L.</given-names></name> <name><surname>Holt</surname> <given-names>A. C.</given-names></name> <name><surname>Medzhitov</surname> <given-names>R.</given-names></name> <name><surname>Flavell</surname> <given-names>R. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3</article-title>. <source>Nature</source> <volume>413</volume>, <fpage>732</fpage>&#x02013;<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1038/35099560</pub-id><pub-id pub-id-type="pmid">11607032</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>E. S.</given-names></name> <name><surname>R&#x000F8;dgaard-Hansen</surname> <given-names>S.</given-names></name> <name><surname>Moessner</surname> <given-names>B.</given-names></name> <name><surname>Christensen</surname> <given-names>P. B.</given-names></name> <name><surname>M&#x000F8;ller</surname> <given-names>H. J.</given-names></name> <name><surname>Weis</surname> <given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>33</volume>, <fpage>117</fpage>&#x02013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-013-1936-3</pub-id><pub-id pub-id-type="pmid">24424890</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Askar</surname> <given-names>E.</given-names></name> <name><surname>Ramadori</surname> <given-names>G.</given-names></name> <name><surname>Mihm</surname> <given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection</article-title>. <source>J. Med. Virol.</source> <volume>82</volume>, <fpage>1859</fpage>&#x02013;<lpage>1868</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21893</pub-id><pub-id pub-id-type="pmid">20872712</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="web"><person-group person-group-type="author"><name><surname>Basit</surname> <given-names>H.</given-names></name> <name><surname>Tyagi</surname> <given-names>I.</given-names></name> <name><surname>Koirala</surname> <given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>&#x0201C;Hepatitis C,&#x0201D;</article-title> in <source>StatPearls</source> (<publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>). Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK430897/">http://www.ncbi.nlm.nih.gov/books/NBK430897/</ext-link> (accessed August 27, 2023).</citation>
</ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bordignon</surname> <given-names>M.</given-names></name> <name><surname>Bargagli</surname> <given-names>E.</given-names></name> <name><surname>Agostini</surname> <given-names>C.</given-names></name> <name><surname>Cinetto</surname> <given-names>F.</given-names></name> <name><surname>Baldo</surname> <given-names>V.</given-names></name> <name><surname>Alaibac</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>TLR7 Gln11Leu single nucleotide polymorphism in patients with sarcoidosis</article-title>. <source>Sarcoidosis Vasc. Diffuse Lung. Dis.</source> <volume>30</volume>, <fpage>157</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">24071890</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname> <given-names>X.-W.</given-names></name> <name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Wang</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Relationship between TLR3 polymorphisms and disease progression in patients with chronic HCV infection combined with HIV infection</article-title>. <source>Chin. J. Integr. Tradit. West. Med. Dig.</source> <volume>25</volume>, <fpage>965</fpage>&#x02013;<lpage>969</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1671-038X.2017.12.17</pub-id></citation>
</ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Citores</surname> <given-names>M. J.</given-names></name> <name><surname>P&#x000E9;rez-Pulgar</surname> <given-names>S.</given-names></name> <name><surname>Duca</surname> <given-names>A.</given-names></name> <name><surname>Crespo</surname> <given-names>G.</given-names></name> <name><surname>de la Fuente</surname> <given-names>S.</given-names></name> <name><surname>Vilches</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by toll-like receptor 3 polymorphism</article-title>. <source>Clin. Transpl.</source> <volume>30</volume>, <fpage>810</fpage>&#x02013;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1111/ctr.12754</pub-id><pub-id pub-id-type="pmid">27101936</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dao Thi</surname> <given-names>V. L.</given-names></name> <name><surname>Dreux</surname> <given-names>M.</given-names></name> <name><surname>Cosset</surname> <given-names>F.-L.</given-names></name></person-group> (<year>2011</year>). <article-title>Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation</article-title>. <source>Expert. Rev. Mol. Med.</source> <volume>13</volume>, <fpage>e13</fpage>. <pub-id pub-id-type="doi">10.1017/S1462399411001785</pub-id><pub-id pub-id-type="pmid">21489334</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fakhir</surname> <given-names>F.-Z.</given-names></name> <name><surname>Lkhider</surname> <given-names>M.</given-names></name> <name><surname>Badre</surname> <given-names>W.</given-names></name> <name><surname>Alaoui</surname> <given-names>R.</given-names></name> <name><surname>Meurs</surname> <given-names>E. F.</given-names></name> <name><surname>Pineau</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression</article-title>. <source>Liver. Int.</source> <volume>38</volume>, <fpage>432</fpage>&#x02013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1111/liv.13533</pub-id><pub-id pub-id-type="pmid">28752959</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gantzel</surname> <given-names>R. H.</given-names></name> <name><surname>Kj&#x000E6;r</surname> <given-names>M. B.</given-names></name> <name><surname>Laursen</surname> <given-names>T. L.</given-names></name> <name><surname>Kazankov</surname> <given-names>K.</given-names></name> <name><surname>George</surname> <given-names>J.</given-names></name> <name><surname>M&#x000F8;ller</surname> <given-names>H. J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibrosis</article-title>. <source>Front. Med.</source> <volume>7</volume>, <fpage>615599</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.615599</pub-id><pub-id pub-id-type="pmid">33490096</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grove</surname> <given-names>J.</given-names></name> <name><surname>Huby</surname> <given-names>T.</given-names></name> <name><surname>Stamataki</surname> <given-names>Z.</given-names></name> <name><surname>Vanwolleghem</surname> <given-names>T.</given-names></name> <name><surname>Meuleman</surname> <given-names>P.</given-names></name> <name><surname>Farquhar</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity</article-title>. <source>J. Virol.</source> <volume>81</volume>, <fpage>3162</fpage>&#x02013;<lpage>3169</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02356-06</pub-id><pub-id pub-id-type="pmid">17215280</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamdy</surname> <given-names>S.</given-names></name> <name><surname>Osman</surname> <given-names>A. M.</given-names></name> <name><surname>Zakaria</surname> <given-names>Z. A.</given-names></name> <name><surname>Galal</surname> <given-names>I.</given-names></name> <name><surname>Sobhy</surname> <given-names>M.</given-names></name> <name><surname>Hashem</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians</article-title>. <source>Arch. Virol.</source> <volume>163</volume>, <fpage>2433</fpage>&#x02013;<lpage>2442</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-018-3893-8</pub-id><pub-id pub-id-type="pmid">29860675</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hedayat</surname> <given-names>M.</given-names></name> <name><surname>Netea</surname> <given-names>M. G.</given-names></name> <name><surname>Rezaei</surname> <given-names>N.</given-names></name></person-group> (<year>2011</year>). <article-title>Targeting of Toll-like receptors: a decade of progress in combating infectious diseases</article-title>. <source>Lancet Infect. Dis.</source> <volume>11</volume>, <fpage>702</fpage>&#x02013;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70099-8</pub-id><pub-id pub-id-type="pmid">21719349</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname> <given-names>J. P. T.</given-names></name> <name><surname>Thompson</surname> <given-names>S. G.</given-names></name></person-group> (<year>2002</year>). <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat. Med.</source> <volume>21</volume>, <fpage>1539</fpage>&#x02013;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1002/sim.1186</pub-id></citation>
</ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Z.-Q.</given-names></name> <name><surname>Jiang</surname> <given-names>Q.-F.</given-names></name> <name><surname>Han</surname> <given-names>Y.-Y.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Gao</surname> <given-names>J.-H.</given-names></name> <name><surname>Ma</surname> <given-names>K.-L.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Progress of the correlations between HLA genes polymorphisms and HCV infection</article-title>. <source>Lett. Biotechnol.</source> <volume>33</volume>, <fpage>131</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1009-0002.2014.01.033</pub-id></citation>
</ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname> <given-names>T.</given-names></name> <name><surname>Akira</surname> <given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title>. <source>Immunity</source> <volume>34</volume>, <fpage>637</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="pmid">21616434</pub-id></citation></ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayesh</surname> <given-names>M. E. H.</given-names></name> <name><surname>Kohara</surname> <given-names>M.</given-names></name> <name><surname>Tsukiyama-Kohara</surname> <given-names>K.</given-names></name></person-group> (<year>2022</year>). <article-title>Toll-like receptor response to hepatitis C virus infection: a recent overview</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>5475</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23105475</pub-id><pub-id pub-id-type="pmid">35628287</pub-id></citation></ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname> <given-names>S. N.</given-names></name> <name><surname>Li</surname> <given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Toll-like receptors in antiviral innate immunity</article-title>. <source>J. Mol. Biol.</source> <volume>426</volume>, <fpage>1246</fpage>&#x02013;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2013.11.024</pub-id><pub-id pub-id-type="pmid">24316048</pub-id></citation></ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>T.-L.</given-names></name> <name><surname>Chen</surname> <given-names>Y.-M.</given-names></name> <name><surname>Hsieh</surname> <given-names>S.-L.</given-names></name> <name><surname>Tang</surname> <given-names>K.-T.</given-names></name> <name><surname>Chen</surname> <given-names>D.-Y.</given-names></name> <name><surname>Yang</surname> <given-names>Y.-Y.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Hepatitis C virus-induced exosomal MicroRNAs and Toll-Like Receptor 7 polymorphism regulate B-cell activating factor</article-title>. <source>mBio</source> <volume>12</volume>, <fpage>e0276421</fpage>. <pub-id pub-id-type="doi">10.1128/mBio.02764-21</pub-id><pub-id pub-id-type="pmid">34724826</pub-id></citation></ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malov</surname> <given-names>S. I.</given-names></name> <name><surname>Baatarkhuu</surname> <given-names>O.</given-names></name> <name><surname>Ogarkov</surname> <given-names>O. B.</given-names></name> <name><surname>Ariunaa</surname> <given-names>S.</given-names></name> <name><surname>Baigalmaa</surname> <given-names>J.</given-names></name> <name><surname>Davaakhuu</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>The role of human genetic factors in the natural selection of hepatitis C virus&#x00027; dominant genotype in ethnically close populations of buryats and Khalkha-Mongols</article-title>. <source>Sovrem. Tehnol. Med.</source> <volume>10</volume>, <fpage>21</fpage>. <pub-id pub-id-type="doi">10.17691/stm2018.10.3.3</pub-id></citation>
</ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazzaro</surname> <given-names>C.</given-names></name> <name><surname>Quartuccio</surname> <given-names>L.</given-names></name> <name><surname>Adinolfi</surname> <given-names>L. E.</given-names></name> <name><surname>Roccatello</surname> <given-names>D.</given-names></name> <name><surname>Pozzato</surname> <given-names>G.</given-names></name> <name><surname>Nevola</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy</article-title>. <source>Viruses</source> <volume>13</volume>, <fpage>2249</fpage>. <pub-id pub-id-type="doi">10.3390/v13112249</pub-id><pub-id pub-id-type="pmid">34835054</pub-id></citation></ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname> <given-names>Y.</given-names></name> <name><surname>Gao</surname> <given-names>Y.</given-names></name> <name><surname>Du</surname> <given-names>Z.</given-names></name></person-group> (<year>2012</year>). <article-title>Research progress on the association between IL-28B gene polymorphism and hepatitis C</article-title>. <source>Int. J. Genet.</source> <volume>35</volume>, <fpage>224</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.issn.1673-4386.2012.04.007</pub-id></citation>
</ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miya</surname> <given-names>T. V.</given-names></name> <name><surname>Groome</surname> <given-names>M. J.</given-names></name> <name><surname>de Assis Rosa</surname> <given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine</article-title>. <source>Vaccine</source> <volume>39</volume>, <fpage>7028</fpage>&#x02013;<lpage>7035</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.10.051</pub-id><pub-id pub-id-type="pmid">34740476</pub-id></citation></ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000F8;ller-Larsen</surname> <given-names>S.</given-names></name> <name><surname>Nyegaard</surname> <given-names>M.</given-names></name> <name><surname>Haagerup</surname> <given-names>A.</given-names></name> <name><surname>Vestbo</surname> <given-names>J.</given-names></name> <name><surname>Kruse</surname> <given-names>T. A.</given-names></name> <name><surname>B&#x000F8;rglum</surname> <given-names>A. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders</article-title>. <source>Thorax</source> <volume>63</volume>, <fpage>1064</fpage>&#x02013;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2007.094128</pub-id><pub-id pub-id-type="pmid">18682521</pub-id></citation></ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosaad</surname> <given-names>Y. M.</given-names></name> <name><surname>Metwally</surname> <given-names>S. S.</given-names></name> <name><surname>Farag</surname> <given-names>R. E.</given-names></name> <name><surname>Lotfy</surname> <given-names>Z. F.</given-names></name> <name><surname>AbdelTwab</surname> <given-names>H. E.</given-names></name></person-group> (<year>2018</year>). <article-title>Association between <italic>Toll-Like Receptor 3</italic> (<italic>TLR3</italic>) rs3775290, <italic>TLR7</italic> rs179008, <italic>TLR9</italic> rs352140 and Chronic HCV</article-title>. <source>Immunol. Investig.</source> <volume>48</volume>, <fpage>321</fpage>&#x02013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1080/08820139.2018.1527851</pub-id><pub-id pub-id-type="pmid">30321082</pub-id></citation></ref>
<ref id="B28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>D.-Y.</given-names></name> <name><surname>Baumann</surname> <given-names>K.</given-names></name> <name><surname>Hamouda</surname> <given-names>O.</given-names></name> <name><surname>Eckert</surname> <given-names>J. K.</given-names></name> <name><surname>Neumann</surname> <given-names>K.</given-names></name> <name><surname>K&#x000FC;cherer</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression</article-title>. <source>AIDS</source> <volume>23</volume>, <fpage>297</fpage>&#x02013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32831fb540</pub-id><pub-id pub-id-type="pmid">19114863</pub-id></citation></ref>
<ref id="B29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piaserico</surname> <given-names>S.</given-names></name> <name><surname>Michelotto</surname> <given-names>A.</given-names></name> <name><surname>Frigo</surname> <given-names>A. C.</given-names></name> <name><surname>Alaibac</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study</article-title>. <source>Pharmacogenomics</source> <volume>16</volume>, <fpage>1913</fpage>&#x02013;<lpage>1917</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.15.132</pub-id><pub-id pub-id-type="pmid">26556041</pub-id></citation></ref>
<ref id="B30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname> <given-names>I.</given-names></name> <name><surname>Cona</surname> <given-names>C.</given-names></name> <name><surname>Saponeri</surname> <given-names>A.</given-names></name> <name><surname>Bassetto</surname> <given-names>F.</given-names></name> <name><surname>Baldo</surname> <given-names>V.</given-names></name> <name><surname>Alaibac</surname> <given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma</article-title>. <source>Biomed. Rep.</source> <volume>4</volume>, <fpage>459</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.3892/br.2016.597</pub-id><pub-id pub-id-type="pmid">27073632</pub-id></citation></ref>
<ref id="B31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabado</surname> <given-names>R. L.</given-names></name> <name><surname>Pavlick</surname> <given-names>A.</given-names></name> <name><surname>Gnjatic</surname> <given-names>S.</given-names></name> <name><surname>Cruz</surname> <given-names>C. M.</given-names></name> <name><surname>Vengco</surname> <given-names>I.</given-names></name> <name><surname>Hasan</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma</article-title>. <source>Cancer Immunol. Res.</source> <volume>3</volume>, <fpage>278</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0202</pub-id><pub-id pub-id-type="pmid">25633712</pub-id></citation></ref>
<ref id="B32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Said</surname> <given-names>E. A.</given-names></name> <name><surname>Al-Yafei</surname> <given-names>F.</given-names></name> <name><surname>Zadjali</surname> <given-names>F.</given-names></name> <name><surname>Hasson</surname> <given-names>S. S.</given-names></name> <name><surname>Al-Balushi</surname> <given-names>M. S.</given-names></name> <name><surname>Al-Mahruqi</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Association of single-nucleotide polymorphisms in TLR7 (Gln11Leu) and TLR9 (1635A/G) with a higher CD4T cell count during HIV infection</article-title>. <source>Immunol. Lett.</source> <volume>160</volume>, <fpage>58</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2014.04.005</pub-id><pub-id pub-id-type="pmid">24747071</pub-id></citation></ref>
<ref id="B33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname> <given-names>S.</given-names></name> <name><surname>Mukherjee</surname> <given-names>S.</given-names></name> <name><surname>Bhattacharya</surname> <given-names>N.</given-names></name> <name><surname>Tripathi</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Differential genotypic signatures of Toll-like receptor polymorphisms among dengue-chikungunya mono- and co-infected Eastern Indian patients</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>40</volume>, <fpage>1369</fpage>&#x02013;<lpage>1381</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-020-04125-x</pub-id><pub-id pub-id-type="pmid">33495940</pub-id></citation></ref>
<ref id="B34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sghaier</surname> <given-names>I.</given-names></name> <name><surname>Mouelhi</surname> <given-names>L.</given-names></name> <name><surname>Ghazoueni</surname> <given-names>E.</given-names></name> <name><surname>Brochot</surname> <given-names>E.</given-names></name> <name><surname>Almawi</surname> <given-names>W. Y.</given-names></name> <name><surname>Yacoubi-Loueslati</surname> <given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population</article-title>. <source>Cytokine</source> <volume>99</volume>, <fpage>297</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2017.08.010</pub-id><pub-id pub-id-type="pmid">28823914</pub-id></citation></ref>
<ref id="B35">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sghaier</surname> <given-names>I.</given-names></name> <name><surname>Zidi</surname> <given-names>S.</given-names></name> <name><surname>Mouelhi</surname> <given-names>L.</given-names></name> <name><surname>Ghazoueni</surname> <given-names>E.</given-names></name> <name><surname>Brochot</surname> <given-names>E.</given-names></name> <name><surname>Almawi</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title><italic>TLR3</italic> and <italic>TLR4</italic> SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection</article-title>. <source>Br. J. Biomed. Sci.</source> <volume>76</volume>, <fpage>35</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1080/09674845.2018.1547179</pub-id><pub-id pub-id-type="pmid">30421643</pub-id></citation></ref>
<ref id="B36">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>H.</given-names></name> <name><surname>He</surname> <given-names>H.</given-names></name> <name><surname>Sun</surname> <given-names>C.</given-names></name> <name><surname>Fu</surname> <given-names>J.</given-names></name> <name><surname>Ghosh</surname> <given-names>D.</given-names></name> <name><surname>Deng</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Association of toll-like receptor polymorphisms with acquisition of HIV infection and clinical findings: A protocol for systematic review and meta-analysis</article-title>. <source>Medicine</source> <volume>99</volume>, <fpage>e23663</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000023663</pub-id><pub-id pub-id-type="pmid">33350746</pub-id></citation></ref>
<ref id="B37">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sizova</surname> <given-names>L.</given-names></name> <name><surname>Koval</surname> <given-names>T.</given-names></name> <name><surname>Kaidashev</surname> <given-names>I.</given-names></name> <name><surname>Ilchenko</surname> <given-names>V.</given-names></name> <name><surname>Dubinskaya</surname> <given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of genetic polymorphisms toll-like receptor 4 and 7 in the chronic hepatitis c and gender features of their distribution</article-title>. <source>Georgian. Med. News</source> <volume>250</volume>, <fpage>51</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">26870975</pub-id></citation></ref>
<ref id="B38">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stang</surname> <given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur. J. Epidemiol.</source> <volume>25</volume>, <fpage>603</fpage>&#x02013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id><pub-id pub-id-type="pmid">20652370</pub-id></citation></ref>
<ref id="B39">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talaat</surname> <given-names>R. M.</given-names></name> <name><surname>Elsayed</surname> <given-names>S. S.</given-names></name> <name><surname>Abdel-Hakem</surname> <given-names>N. E.</given-names></name> <name><surname>El-Shenawy</surname> <given-names>S. Z.</given-names></name></person-group> (<year>2022</year>). <article-title>Genetic polymorphism in toll-like receptor 3 and interferon regulatory factor 3 in hepatitis C virus-infected patients: correlation with liver cirrhosis</article-title>. <source>Viral. Immunol.</source> <volume>35</volume>, <fpage>609</fpage>&#x02013;<lpage>615</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2022.0058</pub-id><pub-id pub-id-type="pmid">36048530</pub-id></citation></ref>
<ref id="B40">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>T&#x000F6;rm&#x000E4;nen</surname> <given-names>S.</given-names></name> <name><surname>Korppi</surname> <given-names>M.</given-names></name> <name><surname>Ter&#x000E4;sj&#x000E4;rvi</surname> <given-names>J.</given-names></name> <name><surname>Vuononvirta</surname> <given-names>J.</given-names></name> <name><surname>Koponen</surname> <given-names>P.</given-names></name> <name><surname>Helminen</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Polymorphism in the gene encoding toll-like receptor 10 may be associated with asthma after bronchiolitis</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>2956</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-03429-x</pub-id><pub-id pub-id-type="pmid">28592890</pub-id></citation></ref>
<ref id="B41">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valverde-Villegas</surname> <given-names>J. M.</given-names></name> <name><surname>Dos Santos</surname> <given-names>B. P.</given-names></name> <name><surname>de Medeiros</surname> <given-names>R. M.</given-names></name> <name><surname>Mattevi</surname> <given-names>V. S.</given-names></name> <name><surname>Lazzaretti</surname> <given-names>R. K.</given-names></name> <name><surname>Sprinz</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Endosomal toll-like receptor gene polymorphisms and susceptibility to HIV and HCV co-infection - Differential influence in individuals with distinct ethnic background</article-title>. <source>Hum. Immunol.</source> <volume>78</volume>, <fpage>221</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2017.01.001</pub-id><pub-id pub-id-type="pmid">28062211</pub-id></citation></ref>
<ref id="B42">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>P.-Q.</given-names></name> <name><surname>Hu</surname> <given-names>C.-M.</given-names></name> <name><surname>Ye</surname> <given-names>X.-G.</given-names></name> <name><surname>Wu</surname> <given-names>S.-W.</given-names></name></person-group> (<year>2013</year>). <article-title>Research progress on individualized treatment of chronic hepatitis C</article-title>. <source>J. Microbes. Infect.</source> <volume>19</volume>, <fpage>186</fpage>&#x02013;<lpage>191</lpage>.</citation>
</ref>
<ref id="B43">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zayed</surname> <given-names>R. A.</given-names></name> <name><surname>Omran</surname> <given-names>D.</given-names></name> <name><surname>Mokhtar</surname> <given-names>D. A.</given-names></name> <name><surname>Zakaria</surname> <given-names>Z.</given-names></name> <name><surname>Ezzat</surname> <given-names>S.</given-names></name> <name><surname>Soliman</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Association of toll-like receptor 3 and toll-like receptor 9 single nucleotide polymorphisms with hepatitis C virus infection and hepatic fibrosis in egyptian patients</article-title>. <source>Am. J. Trop. Med. Hyg.</source> <volume>16</volume>, <fpage>0644</fpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.16-0644</pub-id><pub-id pub-id-type="pmid">28093541</pub-id></citation></ref>
</ref-list>
</back>
</article>